Tralokinumab achieves primary and secondary endpoints in three pivotal Phase 3 trials in adult patients with moderate-to-severe atopic dermatitis
June 12, 2020
Eric Simpson, M.D., notes “there is a critical need for additional treatment options” for patients with moderate to severe atopic dermatitis in a Leo Pharma news release about the efficacy and safety of tralokinumab in treating the condition.